CLDI

Public Offering Announcement: Calidi Biotherapeutics has successfully closed an underwritten public offering, raising $6.9 million in gross proceeds, including the full exercise of the underwriters' over-allotment option.

Details of Securities Sold: The offering included 1,922,764 common stock units and 1,528,000 pre-funded warrant units, with prices set at $2.00 per Common Stock Unit and $1.999 per Pre-Funded Unit.

Company Overview: Calidi Biotherapeutics is focused on developing targeted therapies for cancer treatment, utilizing its proprietary Redtail platform to deliver genetic medicines to metastatic sites.

Forward-Looking Statements: The press release contains forward-looking statements regarding the company's future developments and potential risks associated with clinical trials and capital raising efforts.

U.S. Stock Market Performance: U.S. stocks declined mid-session, with the Nasdaq Composite dropping over 200 points and the S&P 500 and Dow also experiencing losses.

Lowe's Earnings Report: Lowe's Companies reported better-than-expected second-quarter earnings, with adjusted EPS rising to $4.33 and quarterly sales reaching $23.96 billion, prompting an update in fiscal guidance.

Equities Movement: NovaBay Pharmaceuticals saw a significant stock increase of 68% after a securities purchase agreement, while enVVeno Medical Corporation shares plummeted 72% following FDA news.

Global Market Trends: European shares showed mixed results, Asian markets closed mixed with Japan's Nikkei falling, and U.S. mortgage applications decreased by 1.4% from the previous week.

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow Jones gaining over 100 points, while NASDAQ and S&P 500 experienced declines.

Target Corporation Earnings Report: Target's shares fell about 9% despite reporting adjusted earnings per share of $2.05, beating estimates, but sales declined year-over-year.

Notable Stock Movements: NovaBay Pharmaceuticals saw a significant increase of 104% after a securities purchase agreement, while enVVeno Medical Corp dropped 70% due to FDA non-approval.

Global Market Trends: European and Asian markets closed mixed, with varying performances across major indices, and U.S. mortgage applications decreased by 1.4%.